SPRO: Multiplikator Forward P/S Spero Therapeutics

Long-term patent protection and stable hospital demand provide Spero Therapeutics (SPRO) with sustainable revenue. The projected P/S ratio helps assess business maturity, while the 1.40 level reflects the current value of the metric. Current cash flow is supported by grants and licensing payments, minimizing capital expenditure. The development of antibiotics against superbugs addresses global medical challenges, guaranteeing support from government entities.

SPRO Spero Therapeutics, Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 13.11.2026

Rincian analitis perusahaan Spero Therapeutics

- rega saham lan target rega konsensus:

Kutipan saham Spero Therapeutics, Inc.|SPRO - Rega prakiraan analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar Spero Pharma|SPRO - Rega Tumbas Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham Spero Therapeutics|SPRO - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku sperotherapeutics.com|SPRO - Total Aset Bisnis

- data liabilitas lan likuiditas perusahaan:

Utang marang Ekuitas Spero Therapeutics|SPRO - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Spero Therapeutics|SPRO - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Spero Pharma|SPRO - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Spero Therapeutics|Likuiditas cepet sperotherapeutics.com

- data bathi bisnis lan rasio investasi:

SPRO - Bathi pungkasan|Bathi sing dikarepake Spero Therapeutics|SPRO - Kapitalisasi marang bathi|Prakiraan rega marang bathi Spero|SPRO - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Spero Pharma|SPRO - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Spero Therapeutics|SPRO - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan sperotherapeutics.com|SPRO - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Spero Therapeutics

- rincian pendapatan lan dodolan:

SPRO - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Spero Therapeutics, Inc.|SPRO - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Spero Pharma

Analisis komprehensif perusahaan:SPRO (Spero Therapeutics, Inc.)

Conservative capital demands transparency in the valuation of future cash flows to minimize risks within the biotechnology sector. This indicator measures a company's market value relative to expected sales volume, reflecting investor optimism through the forward price-to-sales ratio. For Spero Therapeutics (SPRO), where demand for antibiotics remains independent of economic cycles, the dynamics of this metric serve as a precise barometer of confidence in capital-intensive drug development.

Pesaing langsung

Summit Therapeutics Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake MRNA (Moderna Inc)|Vaxcyte Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Tarsus Corp TARS|CorMedix Inc. (CRMD) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep serestherapeutics.com (MCRB)|Rasio rega marang prakiraan pendapatan SCYNEXIS Inc|Kapitalisasi marang prakiraan pendapatan ANTX (AN2 Bio)|Rasio rega marang prakiraan pendapatan PolyPid Ltd. (PYPD)|Rasio kapitalisasi marang dodolan sing dikarepake YS Biopharma Co., Ltd.|Rasio rega marang prakiraan pendapatan Iterum Therapeutics ITRM|Rasio kapitalisasi marang dodolan sing dikarepake BiomX Inc (PHGE)|SNGX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan SXTP|OGEN: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OpGen Corporation (OPGN)